DeepMed Research

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Cognitive Effects of Atomoxetine in Humans: Genetic Moderators

Not Applicable

Completed

Conditions: Addiction

Interventions: Drug: Sugar Pill
Drug: Atomoxetine

First Posted Date: 2011-12-23

Last Posted Date: 2017-07-11

Lead Sponsor: Yale University

Target Recruit Count: 35

Registration Number: NCT01498549

Locations: 🇺🇸
Department of Veterans Affairs, West Haven, Connecticut, United States

Nicotine Reinforcement and Aversion in Young Adult Light Smokers

Early Phase 1

Completed

Conditions: Nicotine Addiction

Interventions: Drug: Saline
Drug: Nicotine

First Posted Date: 2011-12-20

Last Posted Date: 2021-08-31

Lead Sponsor: Yale University

Target Recruit Count: 34

Registration Number: NCT01495819

Locations: 🇺🇸
Department of Veterans Affairs, West Haven, Connecticut, United States

Plasma Angiopoietin Levels in Children Following Cardiopulmonary Bypass

Completed

Conditions: Congenital Heart Defects

First Posted Date: 2011-12-09

Last Posted Date: 2015-02-26

Lead Sponsor: Yale University

Target Recruit Count: 31

Registration Number: NCT01489475

Locations: 🇺🇸
Yale Children's Hospital, New Haven, Connecticut, United States

Novel Treatments to Enhance Smoking Cessation Before Cancer Surgery: Effects on Smoking and Surgical Outcomes

Phase 1

Terminated

Conditions: Smoking Cessation

Interventions: Other: standard care
Other: standard care plus contingency management

First Posted Date: 2011-11-28

Last Posted Date: 2020-03-09

Lead Sponsor: Yale University

Target Recruit Count: 8

Registration Number: NCT01479998

Locations: 🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease

Not Applicable

Completed

Conditions: Wilson Disease

Interventions: Drug: Once a day Trientine

First Posted Date: 2011-11-17

Last Posted Date: 2020-04-15

Lead Sponsor: Yale University

Target Recruit Count: 8

Registration Number: NCT01472874

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Maintenance lenalidomide

First Posted Date: 2011-11-04

Last Posted Date: 2014-10-23

Lead Sponsor: Yale University

Target Recruit Count: 2

Registration Number: NCT01465230

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Using Capnography to Reduce Hypoxia During Pediatric Sedation

Not Applicable

Completed

Conditions: Hypoventilation
Hypoxia

Interventions: Device: Nellcor NPB-70 Capnograph

First Posted Date: 2011-11-02

Last Posted Date: 2018-01-11

Lead Sponsor: Yale University

Target Recruit Count: 167

Registration Number: NCT01463527

Locations: 🇺🇸
Yale-New Haven Children's Hospital, New Haven, Connecticut, United States

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

Not Applicable

Completed

Conditions: Hypoglycemia

Interventions: Drug: Naltrexone High Dose
Drug: Naltrexone Low Dose

First Posted Date: 2011-10-31

Last Posted Date: 2016-02-18

Lead Sponsor: Yale University

Target Recruit Count: 17

Registration Number: NCT01462227

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

Minding the Baby Home Visiting: Program Evaluation

Not Applicable

Completed

Conditions: Child Maltreatment
Maternal Sensitivity
Attachment
Infant Health

Interventions: Behavioral: Minding the Baby Home Visiting Program

First Posted Date: 2011-10-24

Last Posted Date: 2018-01-17

Lead Sponsor: Yale University

Target Recruit Count: 151

Registration Number: NCT01458145

Locations: 🇺🇸
Fair Haven Community Health Center, New Haven, Connecticut, United States
🇺🇸
Cornell Scott Hill Health Center, New Haven, Connecticut, United States

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

Phase 1

Completed

Conditions: Cholangitis, Sclerosing

Interventions: Drug: Oral all-trans retinoic acid (ATRA)

First Posted Date: 2011-10-20

Last Posted Date: 2016-07-14

Lead Sponsor: Yale University

Target Recruit Count: 19

Registration Number: NCT01456468

Locations: 🇺🇸
Yale University School of Medicine - 333 Cedar St - 1080 LMP, New Haven, Connecticut, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy